Helsinn Group, of Lugano, Switzerland, said it granted exclusive distribution and licensing rights to Gruppo Angelini SpA, of Rome, for the commercialization in Austria, Bulgaria, Czech Republic, Hungary, Poland, Romania, Slovak Republic, Georgia, Russia and the other CIS countries of its compound in development for anorexia-cachexia syndrome related to non-small-cell lung cancer.